drugset / Trial / NCT05703672

Switching to E-cigarettes in Smokers Not Interested in Quitting

NCT05703672

Phase 3 Recruiting 500 enrolled University of Kansas Medical Center
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The objectives of this application are to 1) compare short- and long-term harm reduction and abuse liability potential of a nicotine salt pod-based electronic cigarettes (EC) in adult (AA) exclusive EC, dual cig-EC, and exclusive cig users, 2) characterize factors that predict who switches fully, partially, or not at all, and 3) examine if harm reduction can be further enhanced by treating dual users with varenicline (VAR) to eliminate cigarette smoking.

Timeline

Start
2023-07-17
Primary completion
2026-12-07
Completion
2027-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 1 mg

Indications

No indication recorded.